AnPac Bio-Medical Science (ANPC) Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021

Go back to AnPac Bio-Medical Science (ANPC) Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021

AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020

April 16, 2021 4:15 PM EDT

SAN JOSE, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (AnPac Bio, the Company or we) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its paid tests based on the cancer differentiation analysis technology (CDA) technology, or paid CDA-based tests, in the first quarter of 2021, setting a record high Q1 test volume. CDA-based tests, which are multi-cancer tests based on a novel biophysical approach, are the Companys flagship product line and... More